Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026)
Viatris (VTRS) posted quarterly Liabilities and Shareholders Equity of $36.8 billion for Q1 2026, down 4.26% year-over-year from $38.5 billion in Q1 2025, and down 0.96% quarter-over-quarter from $37.2 billion in Q4 2025.
Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Viatris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $36.8 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 4.26% year-over-year to $36.8 billion; the TTM figure through Mar 2026 stood at $150.4 billion (down 11.58% YoY), while the FY2025 annual figure was $37.2 billion, down 10.38% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $36.8 billion, down from $37.2 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $53.5 billion in Q1 2022, with the low at $36.8 billion in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $47.3 billion (2024), against an average of $45.0 billion.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity climbed 0.16% in 2023, then decreased 18.73% in 2025.
- Viatris' Liabilities and Shareholders Equity stood at $50.0 billion in 2022, then retreated by 4.67% to $47.7 billion in 2023, then retreated by 12.97% to $41.5 billion in 2024, then decreased by 10.38% to $37.2 billion in 2025, then decreased by 0.96% to $36.8 billion in 2026.
- Business Quant data shows VTRS's Liabilities and Shareholders Equity at $36.8 billion in Q1 2026, $37.2 billion in Q4 2025, and $37.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 4.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.04 Bn |
| Mar 31, 2026 | 36.83 Bn |
| Dec 31, 2025 | 37.19 Bn |
| Sep 30, 2025 | 37.92 Bn |
| Jun 30, 2025 | 38.41 Bn |
| Mar 31, 2025 | 38.47 Bn |
| Dec 31, 2024 | 41.50 Bn |
| Sep 30, 2024 | 44.75 Bn |
| Jun 30, 2024 | 45.33 Bn |
| Mar 31, 2024 | 47.34 Bn |
| Dec 31, 2023 | 47.69 Bn |
| Sep 30, 2023 | 48.74 Bn |
| Jun 30, 2023 | 48.70 Bn |
| Mar 31, 2023 | 49.29 Bn |
| Dec 31, 2022 | 50.02 Bn |
| Sep 30, 2022 | 48.66 Bn |
| Jun 30, 2022 | 51.13 Bn |
| Mar 31, 2022 | 53.47 Bn |
| Dec 31, 2021 | 54.84 Bn |
| Sep 30, 2021 | 56.07 Bn |